CD8A and neoplasm: Since POLθ inhibitors are only just entering early phase clinical trials (e.g., NCT04991480 and NCT05687110), it will be important to confirm our preclinical findings of cGAS/STING pathway activation and increased CD8+ T-cell recruitment using paired tumor biopsies to interrogate the immune microenvironment.